
Metformin (1000mg) + Sitagliptin (50mg)
Active composition
+1 more active ingredient
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Sitagliptin inhibits DPP-4, increasing incretin levels, which stimulate insulin release and reduce glucagon secretion.
Medical applications
Lupisit M 50mg/1000mg Tablet is a combination oral antidiabetic medication containing Sitagliptin 50mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by increasing levels of active glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby promoting insulin release and suppressing glucagon secretion in a glucose-dependent manner. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake. The combination of these agents provides complementary mechanisms to achieve better glycemic control compared to monotherapy. Lupisit M is indicated for adult patients inadequately controlled on diet and exercise alone or on monotherapy with either agent. It is contraindicated in patients with renal impairment, metabolic acidosis, or hypersensitivity to its components. Common adverse effects include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often diminish over time. Regular monitoring of renal function and glycemic parameters is recommended during therapy. Lupisit M should be used as part of a comprehensive diabetes management plan including diet, exercise, and weight control.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Information regarding the use of Lupisit M 50mg/1000mg Tablet during pregnancy is not available. Please consult your doctor.
High Risk
Lupisit M 50mg/1000mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Lupisit M 50mg/1000mg Tablet should be used with caution in patients with kidney disease. Dose adjustment of Lupisit M 50mg/1000mg Tablet may be needed. Please consult your doctor. Use of Lupisit M 50mg/1000mg Tablet is, however, not recommended in patients with severe kidney disease. Regular monitoring of kidney function test is advisable while you are taking this medicine.
Exercise Caution
Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.
Consult Doctor
Lupisit M 50mg/1000mg Tablet is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
0 reviews for Lupisit M 50mg/1000mg Tablet

Sitagliptin (50mg) + Metformin (1000mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+1 more active ingredient
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Sitagliptin inhibits DPP-4, increasing incretin levels, which stimulate insulin release and reduce glucagon secretion.
Medical applications
Lupisit M 50mg/1000mg Tablet is a combination oral antidiabetic medication containing Sitagliptin 50mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by increasing levels of active glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby promoting insulin release and suppressing glucagon secretion in a glucose-dependent manner. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake. The combination of these agents provides complementary mechanisms to achieve better glycemic control compared to monotherapy. Lupisit M is indicated for adult patients inadequately controlled on diet and exercise alone or on monotherapy with either agent. It is contraindicated in patients with renal impairment, metabolic acidosis, or hypersensitivity to its components. Common adverse effects include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often diminish over time. Regular monitoring of renal function and glycemic parameters is recommended during therapy. Lupisit M should be used as part of a comprehensive diabetes management plan including diet, exercise, and weight control.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Information regarding the use of Lupisit M 50mg/1000mg Tablet during pregnancy is not available. Please consult your doctor.
High Risk
Lupisit M 50mg/1000mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Lupisit M 50mg/1000mg Tablet should be used with caution in patients with kidney disease. Dose adjustment of Lupisit M 50mg/1000mg Tablet may be needed. Please consult your doctor. Use of Lupisit M 50mg/1000mg Tablet is, however, not recommended in patients with severe kidney disease. Regular monitoring of kidney function test is advisable while you are taking this medicine.
Exercise Caution
Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.
Consult Doctor
Lupisit M 50mg/1000mg Tablet is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
0 reviews for Lupisit M 50mg/1000mg Tablet













